Data show no evidence of inhaled insulin-related lung cancer
Patients who received inhaled insulin using the AERx insulin Diabetes Management System did not develop primary lung cancer, according to data released by Aradigm Corporation.
Novo Nordisk, Aradigm’s partner in the development of the inhaled insulin, conducted a review of phase 3 clinical trial data in response to a labeling update prompted by Pfizer Incorporated.
This entry was posted on Tuesday, May 6th, 2008 at 3:30 pm and is filed under Research. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.